103 related articles for article (PubMed ID: 31308027)
21. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
22. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
[TBL] [Abstract][Full Text] [Related]
23. Axillary lymph node metastasis detection by magnetic resonance imaging in patients with breast cancer: A meta-analysis.
Zhou P; Wei Y; Chen G; Guo L; Yan D; Wang Y
Thorac Cancer; 2018 Aug; 9(8):989-996. PubMed ID: 29877048
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of preoperative breast magnetic resonance imaging with a dedicated axillary sequence for the detection of axillary lymph node metastasis in patients with early ductal breast cancer.
Ahn HS; Jang M; Kim SM; La Yun B; Lee SH
Radiol Med; 2019 Dec; 124(12):1220-1228. PubMed ID: 31422573
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for sentinel lymph node metastasis and validation study of the MSKCC nomogram in breast cancer patients.
Qiu PF; Liu JJ; Wang YS; Yang GR; Liu YB; Sun X; Wang CJ; Zhang ZP
Jpn J Clin Oncol; 2012 Nov; 42(11):1002-7. PubMed ID: 23100610
[TBL] [Abstract][Full Text] [Related]
26. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population.
Klar M; Jochmann A; Foeldi M; Stumpf M; Gitsch G; Stickeler E; Watermann D
Breast Cancer Res Treat; 2008 Dec; 112(3):523-31. PubMed ID: 18172758
[TBL] [Abstract][Full Text] [Related]
27. Interaction of MRE11 and Clinicopathologic Characteristics in Recurrence of Breast Cancer: Individual and Cumulated Receiver Operating Characteristic Analyses.
Yang CH; Moi SH; Chuang LY; Yuan SF; Hou MF; Lee YC; Chang HW
Biomed Res Int; 2017; 2017():2563910. PubMed ID: 28133604
[TBL] [Abstract][Full Text] [Related]
28. [Long non-coding RNA HOTAIR in plasma as a potential biomarker for breast cancer diagnosis].
Zhang KJ; Zhang Y; Luo ZL; Liu L; Yang J; Wu LC; Yu SS; Liu JB
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):488-92. PubMed ID: 27113175
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
30. Serum Dickkopf-1 acts as a new biomarker in human breast cancer.
Liu JT; Guo WB; Sun JY
Minerva Med; 2017 Aug; 108(4):334-340. PubMed ID: 28248066
[TBL] [Abstract][Full Text] [Related]
31. Nonimage-guided fine needle aspiration biopsy of palpable axillary lymph nodes in breast cancer patients.
Marti JL; Ayo D; Levine P; Hernandez O; Rescigno J; Axelrod DM
Breast J; 2012; 18(1):3-7. PubMed ID: 22098412
[TBL] [Abstract][Full Text] [Related]
32. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
33. Validation of Memorial Sloan-Kettering Cancer Center nomogram for prediction of non-sentinel lymph node metastasis in sentinel lymph node positive breast cancer patients an international comparison.
Kuo YL; Chen WC; Yao WJ; Cheng L; Hsu HP; Lai HW; Kuo SJ; Chen DR; Chang TW
Int J Surg; 2013; 11(7):538-43. PubMed ID: 23707626
[TBL] [Abstract][Full Text] [Related]
34. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
36. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
37. Quantification of Tumor Abnormal Proteins in the Diagnosis and Postoperative Prognostic Evaluation of Gastric Cancer.
Gu C; Xie L; Li B; Zhang L; Li F; Wang W; Su J; Xu Z
Clin Med Insights Oncol; 2022; 16():11795549221104440. PubMed ID: 35774594
[TBL] [Abstract][Full Text] [Related]
38. Differential diagnosis of benign and malignant breast masses using diffusion-weighted magnetic resonance imaging.
Min Q; Shao K; Zhai L; Liu W; Zhu C; Yuan L; Yang J
World J Surg Oncol; 2015 Feb; 13():32. PubMed ID: 25889380
[TBL] [Abstract][Full Text] [Related]
39. Characterization of breast lesion using double phase Tc-99m Tetrofosmin scintimammography: comparison of visual and quantitative analyses.
Lee JS; Kim SJ; Kim IJ; Bae YT; Kim YK; Kang YS; Kim DS
Eur J Radiol; 2006 Jan; 57(1):76-80. PubMed ID: 16125892
[TBL] [Abstract][Full Text] [Related]
40. Classification of breast mass lesions using model-based analysis of the characteristic kinetic curve derived from fuzzy c-means clustering.
Chang YC; Huang YH; Huang CS; Chang PK; Chen JH; Chang RF
Magn Reson Imaging; 2012 Apr; 30(3):312-22. PubMed ID: 22245697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
